Louisville, Kentucky--(Newsfile Corp. - May 19, 2025) - Aura Wellness today announced groundbreaking research demonstrating the effectiveness of its Pulsed Electromagnetic Field (PEMF) technology in ...

Prostate-specific antigen (PSA) screening likely results in a reduction in prostate cancer-specific mortality, according to a review published online May 15 in the Cochrane Database of Systematic ...

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific antigen (PSA) screening. However, the findings also highlight the issue of ...

Observational data suggested that men with nonmetastatic prostate cancer lived longer if they followed a healthier lifestyle. A higher prostate cancer behavior score was associated with reductions in ...

Patients say the difference it makes is amazing. A state-of-the-art laser prostate reduction operation is now being successfully delivered in the county as a day case procedure. HOLEP, or Holmium ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...

Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...

Each 1-point increase in the 2021 Prostate Cancer Behavior Score was significantly associated with a reduction in all-cause mortality. Healthy lifestyle and dietary choices are associated with a ...

To earn CME related to this news article, click here. February 25, 2009 — A new joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association ...

--Johnson& Johnson announced today the U.S. Food and Drug Administration approved the supplemental New Drug Application for AKEEGA ® plus prednisone for the treatment of patients with BRCA2-mutated ...